I think it would be paradoxical if the 148 week data is not presented in the Precision Medicine context that Anavex is focusing on.
I expect the patient’s individual responses will be presented as per the gene variants findings and hope that thereby the outliers who did not do so well despite high A2-73 blood concentration are explained.
As an important bonus is if those outlier patients, was it one or two, that did well with very low A2-73 blood concentration are explained for example through the gut microbiome KEM analysis expansion. In fact getting those explained I think will crucial to how analysts and the market will react.
Market Data 
Markets 
